February 2023

February 10, 2023

From the Co-Chairs, February 2023

Plans for the year ahead; a focus on data; the future of cancer screening studies
February 10, 2023

Now Enrolling: EA8212/BRIDGE for Non-Muscle Invasive Bladder Cancer

This phase 3 study is comparing the efficacy of intravesical chemotherapy after surgery to the usual approach of intravesical immunotherapy after surgery
February 10, 2023

TMIST Passes 80,000 Patients Enrolled

Even as screening mammography volumes remain below pre-pandemic levels, TMIST continues to enroll women at a strong pace
February 10, 2023

Trial Spotlight: A Closer Look at ECOG-ACRIN’s Myeloma Studies

These three trials are open and enrolling adults with multiple myeloma or at high risk of developing the disease
February 10, 2023

Trial Results: ASH Highlights Practice-Changing Results for B-Lineage Acute Lymphoblastic Leukemia

The phase 3 E1910 clinical trial provides strong evidence for adding immunotherapy to standard front-line consolidation chemotherapy
February 10, 2023

Trial Results: ECOG-ACRIN Research Round-Up

Summaries of recently published ECOG-ACRIN research results
February 10, 2023

News in Brief, February 2023

Summaries and links to timely information about research results in medical journals, recognition of research leaders, and more